Effects of cholestyramine on gallbladder and gastric emptying in obese and lean subjects
- 1 October 1995
- journal article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 25 (10) , 746-753
- https://doi.org/10.1111/j.1365-2362.1995.tb01953.x
Abstract
Gallbladder stasis is frequent in obese subjects and may contribute to their increased risk for gallstone formation. The bile salt sequestrant cholestyramine acutely enhances postprandial gallbladder emptying in lean subjects, through dis‐inhibition of a negative feedback between intraluminal bile salts and CCK release. In this study the effect of cholestyramine on both gallbladder and gastric antrum dynamics were studied by realtime ultrasonography in 12 obese and 15 lean subjects. For the acute study, on different days, subjects ingested a liquid meal (two egg yolks plus water 200 mL, 50 kJ) or a meal with 4g cholestyramine. Gallbladder emptying was impaired in obese patients who had significantly larger fasting gallbladder volume (39.4 ± 6.9 vs. 21.6 ± l.7mL, PP< 0.0006) and slower emptying time (T/2: 33 ± 2 vs. 21 ± 2 min, P < 0.05) than lean subjects. Integrated antral emptying was also less in obese than lean subjects (5521 ± 578 vs. 7908 ± 491 % 120min‐1, P<0.02). Cholestyramine enhanced postprandial gallbladder emptying in both obese and lean subjects. Gastric emptying was delayed with cholestyramine in lean but not obese subjects. For the chronic study, after 1 month therapy with cholestyramine (4 g every 2 days), the motility tests were repeated in nine obese subjects. Gallbladder and gastric responses to a test meal, with or without cholestyramine, were preserved. We conclude that both gallbladder and antral emptying of a liquid test meal are impaired in obese subjects. Gallbladder emptying improves after acute administration of a low dose cholestyramine with test meal. This effect is sustained after 1 month treatment with a low dose of cholestyramine and does not interfere with gastric emptying of obese patients. Cholestyramine may improve gallbladder hypomotility in obese people.Keywords
This publication has 38 references indexed in Scilit:
- Cholecystokinin octapeptide stimulates phasic and tonic pyloric motility in healthy humans.Gut, 1993
- Gallbladder hypokinesia and normal gastric emptying of liquids in patients with dyspeptic symptomsDigestive Diseases and Sciences, 1992
- Dissociation of cholecystokinin and pancreaticobiliary response to intraduodenal bile acids and cholestyramine in humansDigestive Diseases and Sciences, 1991
- Role of Cholecystokinin in Cholestyramine-induced Changes of the Exocrine PancreasPancreas, 1991
- Effects of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in humans. Implications for the physiology of CCK.Journal of Clinical Investigation, 1989
- Effects of Ursodeoxycholic Acid and Aspirin on the Formation of Lithogenic Bile and Gallstones during Loss of WeightNew England Journal of Medicine, 1988
- Body Fat and the Activity of the Autonomic Nervous SystemNew England Journal of Medicine, 1988
- Biliary Lipid Composition in ObesityScandinavian Journal of Gastroenterology, 1981
- Effects of Pregnancy and Contraceptive Steroids on Gallbladder FunctionNew England Journal of Medicine, 1980
- ENERGY DENSITY OF FOOD, GASTRIC EMPTYING, AND OBESITYThe Lancet, 1975